U.S. markets open in 2 hours 50 minutes
  • S&P Futures

    4,448.00
    +2.25 (+0.05%)
     
  • Dow Futures

    34,772.00
    +98.00 (+0.28%)
     
  • Nasdaq Futures

    15,273.25
    -45.50 (-0.30%)
     
  • Russell 2000 Futures

    2,252.40
    +8.40 (+0.37%)
     
  • Crude Oil

    75.06
    +1.08 (+1.46%)
     
  • Gold

    1,748.70
    -3.00 (-0.17%)
     
  • Silver

    22.55
    +0.12 (+0.56%)
     
  • EUR/USD

    1.1705
    -0.0012 (-0.11%)
     
  • 10-Yr Bond

    1.4600
    0.0000 (0.00%)
     
  • Vix

    18.37
    -0.26 (-1.40%)
     
  • GBP/USD

    1.3698
    +0.0018 (+0.13%)
     
  • USD/JPY

    110.9420
    +0.2570 (+0.23%)
     
  • BTC-USD

    43,826.86
    +824.67 (+1.92%)
     
  • CMC Crypto 200

    1,091.38
    -11.68 (-1.06%)
     
  • FTSE 100

    7,066.09
    +14.61 (+0.21%)
     
  • Nikkei 225

    30,240.06
    -8.75 (-0.03%)
     

Would Shareholders Who Purchased Orgenesis' (NASDAQ:ORGS) Stock Three Years Be Happy With The Share price Today?

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market index fund. But if you try your hand at stock picking, your risk returning less than the market. Unfortunately, that's been the case for longer term Orgenesis Inc. (NASDAQ:ORGS) shareholders, since the share price is down 17% in the last three years, falling well short of the market return of around 64%. But it's up 8.5% in the last week.

See our latest analysis for Orgenesis

Given that Orgenesis didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. Shareholders of unprofitable companies usually expect strong revenue growth. Some companies are willing to postpone profitability to grow revenue faster, but in that case one does expect good top-line growth.

Over the last three years, Orgenesis' revenue dropped 30% per year. That's definitely a weaker result than most pre-profit companies report. On the face of it we'd posit the share price fall of 5% compound, over three years is well justified by the fundamental deterioration. The key question now is whether the company has the capacity to fund itself to profitability, without more cash. The company will need to return to revenue growth as quickly as possible, if it wants to see some enthusiasm from investors.

You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).

earnings-and-revenue-growth
earnings-and-revenue-growth

If you are thinking of buying or selling Orgenesis stock, you should check out this FREE detailed report on its balance sheet.

A Different Perspective

Investors in Orgenesis had a tough year, with a total loss of 7.7%, against a market gain of about 41%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Regrettably, last year's performance caps off a bad run, with the shareholders facing a total loss of 0.2% per year over five years. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. It's always interesting to track share price performance over the longer term. But to understand Orgenesis better, we need to consider many other factors. Case in point: We've spotted 3 warning signs for Orgenesis you should be aware of, and 1 of them is potentially serious.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.